Tacalcitol structure
|
Common Name | Tacalcitol | ||
---|---|---|---|---|
CAS Number | 57333-96-7 | Molecular Weight | 416.637 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | 565.0±50.0 °C at 760 mmHg | |
Molecular Formula | C27H44O3 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 238.4±24.7 °C | |
Symbol |
GHS06 |
Signal Word | Danger |
Use of TacalcitolTacalcitol (1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3) promotes normal bone development by regulating calcium.IC50 value:Target: Tacalcitol modulates immunological and inflammatory processes. Tacalcitol induces nerve growth factor production in epidermal keratinocytes. |
Name | (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,5R)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol |
---|---|
Synonym | More Synonyms |
Description | Tacalcitol (1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3) promotes normal bone development by regulating calcium.IC50 value:Target: Tacalcitol modulates immunological and inflammatory processes. Tacalcitol induces nerve growth factor production in epidermal keratinocytes. |
---|---|
Related Catalog | |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 565.0±50.0 °C at 760 mmHg |
Molecular Formula | C27H44O3 |
Molecular Weight | 416.637 |
Flash Point | 238.4±24.7 °C |
Exact Mass | 416.329041 |
PSA | 60.69000 |
LogP | 6.12 |
Vapour Pressure | 0.0±3.5 mmHg at 25°C |
Index of Refraction | 1.546 |
Storage condition | Store at -20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H300 |
Hazard Codes | N-T+ |
Risk Phrases | R50/53:Very Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment . R33:Danger of cumulative effects. R26/27/28:Very Toxic by inhalation, in contact with skin and if swallowed . |
Safety Phrases | S61-S60-S45-S36-S28A-S13 |
RIDADR | 2025 |
RTECS | OW2300000 |
Packaging Group | II |
Hazard Class | 6.1 |
Regulation of RANTES and IL-8 production in normal human dermal fibroblasts by active vitamin D3 (tacalcitol).
Br. J. Pharmacol. 124(7) , 1433-8, (1998) 1. The production of chemokines, RANTES and IL-8 in cultured human dermal fibroblasts and the effects of tacalcitol (1alpha,24(R)-dihydroxyvitamin D3) were studied using an enzyme-linked immunosorbent... |
|
Tacalcitol in the treatment of acquired perforating collagenosis. Escribano-Stablé JC
Case Rep. Dermatol. 6(1) , 69-73, (2014)
|
|
Hailey-hailey disease treated with topical tacalcitol. Jeon SY et al
Ann. Dermatol. 25(3) , 389-90, (2013)
|
1a,24R-Dihydroxyvitamin D3 |
TV-02H |
1,3-Cyclohexanediol, 4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,4R)-4-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3S,5Z)- |
(1S,3R,5Z,7E,24R)-9,10-Secocholesta-5,7,10-triene-1,3,24-triol |
Bonalfa |
1a,24(R)-Dihydroxycholecalciferol |
Curatoderm |
(1a,3b,5Z,7E,24R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol |
1,24R-dihydroxyvitamin D3 |
TV-02 |
(+)-(5Z,7E,24R)-9,10-Secocholesta-5,7,10(19)-triene-1α,3β,24-triol |
Tacalcitol |